MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
10.95
+0.15
+1.39%
After Hours: 10.95 0 0.00% 16:01 01/17 EST
OPEN
10.69
PREV CLOSE
10.80
HIGH
10.95
LOW
10.58
VOLUME
48.98K
TURNOVER
--
52 WEEK HIGH
26.37
52 WEEK LOW
8.26
MARKET CAP
939.75M
P/E (TTM)
-47.9842
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GYRE last week (0106-0110)?
Weekly Report · 6d ago
Leadership Changes at Gyre Therapeutics Amid Strategic Shift
TipRanks · 01/06 12:28
Gyre Therapeutics appoints Ping Zhang to board of directors
TipRanks · 01/06 12:12
GYRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF PING ZHANG TO BOARD OF DIRECTORS
Reuters · 01/06 12:00
GYRE THERAPEUTICS INC - SONGJIANG MA APPOINTED CHAIRMAN OF GYRE PHARMACEUTICALS
Reuters · 01/06 12:00
Press Release: Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Dow Jones · 01/06 12:00
Weekly Report: what happened at GYRE last week (1230-0103)?
Weekly Report · 01/06 10:04
Weekly Report: what happened at GYRE last week (1223-1227)?
Weekly Report · 12/30/2024 10:01
More
About GYRE
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.